GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Cyclically Adjusted Book per Share

SELLAS Life Sciences Group (FRA:RXK3) Cyclically Adjusted Book per Share : €1,921.68 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

SELLAS Life Sciences Group's adjusted book value per share for the three months ended in Mar. 2024 was €0.158. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1,921.68 for the trailing ten years ended in Mar. 2024.

During the past 12 months, SELLAS Life Sciences Group's average Cyclically Adjusted Book Growth Rate was -29.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -14.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of SELLAS Life Sciences Group was -12.90% per year. The lowest was -22.50% per year. And the median was -14.60% per year.

As of today (2024-06-15), SELLAS Life Sciences Group's current stock price is €1.35. SELLAS Life Sciences Group's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €1,921.68. SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio of today is 0.00.


SELLAS Life Sciences Group Cyclically Adjusted Book per Share Historical Data

The historical data trend for SELLAS Life Sciences Group's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Cyclically Adjusted Book per Share Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,371.76 3,017.45 2,966.41 2,787.01 2,197.69

SELLAS Life Sciences Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,556.87 2,521.55 2,357.76 2,197.69 1,921.68

Competitive Comparison of SELLAS Life Sciences Group's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio falls into.



SELLAS Life Sciences Group Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SELLAS Life Sciences Group's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.158/131.7762*131.7762
=0.158

Current CPI (Mar. 2024) = 131.7762.

SELLAS Life Sciences Group Quarterly Data

Book Value per Share CPI Adj_Book
201406 5,288.579 100.560 6,930.313
201409 5,912.840 100.428 7,758.525
201412 6,957.176 99.070 9,253.992
201503 10,359.393 99.621 13,703.136
201506 8,160.297 100.684 10,680.287
201509 5,348.889 100.392 7,021.075
201512 2,297.222 99.792 3,033.489
201603 1,839.439 100.470 2,412.594
201606 2,974.671 101.688 3,854.835
201609 2,982.098 101.861 3,857.900
201612 -467.621 101.863 -604.945
201703 1,026.898 102.862 1,315.553
201706 682.011 103.349 869.604
201709 440.459 104.136 557.370
201712 15.164 104.011 19.212
201803 -8.685 105.290 -10.870
201806 -14.390 106.317 -17.836
201809 38.578 106.507 47.731
201812 10.465 105.998 13.010
201903 5.400 107.251 6.635
201906 6.336 108.070 7.726
201909 2.123 108.329 2.583
201912 1.080 108.420 1.313
202003 1.086 108.902 1.314
202006 0.500 108.767 0.606
202009 0.713 109.815 0.856
202012 1.612 109.897 1.933
202103 1.600 111.754 1.887
202106 1.747 114.631 2.008
202109 1.425 115.734 1.623
202112 1.133 117.630 1.269
202203 0.230 121.301 0.250
202206 0.877 125.017 0.924
202209 0.618 125.227 0.650
202212 0.218 125.222 0.229
202303 0.434 127.348 0.449
202306 0.158 128.729 0.162
202309 -0.126 129.860 -0.128
202312 -0.228 129.419 -0.232
202403 0.158 131.776 0.158

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


SELLAS Life Sciences Group  (FRA:RXK3) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.35/1921.68
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


SELLAS Life Sciences Group Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (FRA:RXK3) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines